Waltham, Massachusetts-based Adagio Therapeutics Inc, a developer of antibodies for coronaviruses, has raised $50 million in Series A financing. Polaris Partners and Mithril Capital led the round with participation from other investors that included Fidelity Management & Research Company LLC, OrbiMed, M28 Capital and GV.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: